Changes (mean, SD) from baseline to follow-up at 12 months: OxQUIP versus other PSP studies
| PSPRS change mean (SD) | PSPRS mean change as % of max score | MDS-UPRS III change mean(SD) | MDS-UPRS III mean change as % of max score | MoCA | MMSE | |
| OxQUIP | 6.31 (9.9) | 6.3 | 11.75 (12.3) | 8.9 | – | – |
| Golbe and Ohman-Strickland14 | 11.3 (11.0) | 11.3 | – | – | 2.1 (1.7) | |
| Gosh et al34 | 11.3 | 11.3 | 8.3 | 6.3 | – | – |
| Piot et al (2020)42 | 10.8 (9.4) | 10.8 | 14.8 (18.6) | 11.2 | 1.7 (5.6) | – |
| Bang et al (2017); Boxer et al (2014)35 | 11.1 (9.9 to 12.3)* | 11.1 | – | – | – | |
| Litvan and Kong19 | 9.1 (9.4) | 9.1 | 6.3 (9.2) | 4.8 | – | 2.1 (1.7) |
*Mean (95% CI).
MDS-UPDRS-III, Movement Disorders Society Unified Parkinson’s disease Rating Scale part III; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; OxQUIP, Oxford Quantification in Parkinsonism; PSPRS, Progressive Supranuclear Palsy Rating Scale; SD, Standard deviation.